journal: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

Impact Factor: 0.9

Journal Open Access

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

Official Journal of the Spanish Society of Laboratory Medicine SEMEDLAB

Editor-in-Chief: Wladimiro Jiménez Povedano

Languages: English, Spanish

First published: February 20, 2020

Publication Frequency: 4 issues per year

View latest issue

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

About this journal

Objective: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio (Adv Lab Med) is the official journal of the Spanish Society of Laboratory Medicine (SEMEDLAB). Adv Lab Med publishes contributions in the field of medical sciences, including Biochemistry, Hematology, Toxicology, Microbiology and Parasitology, Immunology, and Genetics. Articles focusing on the choice, performance or interpretation of clinical tests are especially welcome.
Adv Lab Med publishes quarterly. All contributions submitted for publication in Adv Lab Med are single-blind peer reviewed by at least two experts in the field, selected and invited by the Editor-in-Chief. Adv Lab Med is an Open Access journal with an international board of renowned editors. Authors are not charged for manuscript processing and Open Access publication. SEMEDLAB covers processing and publication charges. The Society plays no role in the selection and publication of the articles, nor does it influence peer review. Adv Lab Med is a bilingual journal, and all articles are published in both English and Spanish.

Submissions in the following fields are welcome:

Clinical Chemistry / Clinical Hematology and Coagulation / Genetic and Molecular Biology / Clinical Immunology and Autoimmunity / Clinical Microbiology and Parasitology / Drug Monitoring and Toxicology / Evaluation of Diagnostic Biomarkers / New Technologies and Methodologies / Reference Materials and Methods / Reference Values and Decision Limits / Quality Control / Translational Laboratory Medicine / Endocrinology and Metabolism / Lipids and Lipoproteins / Cardiovascular Risk Factors / Cancer Biomarkers / Clinical Metrology / Laboratory Management / POCT

Article Formats

Research Articles: full length articles and short communications / Reviews and Mini Reviews / Opinion Papers / Editorials / Letters to the Editor and Replies / Case Reports / Guidelines and Recommendations

You can find the Instructions for Authors here.

Your Benefits

Latest developments in the clinical laboratory sciences
Fundamental and applied approach
Novel teaching and training methods
High quality peer-review
Unrestricted funding of open access publication
Authors retain copyright – articles published under the Creative Commons Attribution (CC-BY-4.0) License
Each article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico

History

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio was founded by the Spanish Society of Laboratory Medicine and launched at EuroMedLab 2019 in Barcelona.

Open Access
Pericardial fluid cytology as a diagnostic tool for diffuse large B-cell lymphoma: a case report

October 3, 2025

Antonio Sierra-Rivera, Clara Ramírez-Serra, Laura Sahuquillo-Frias

Download PDF

Objectives Primary cardiac lymphoma represents an extremely rare entity of extranodal non-Hodgkin lymphoma. Case presentation We report the case of a woman who presented with dyspnea, asthenia, chest pain, cough, and odynophagia. Investigations revealed a diffuse large B-cell lymphomas type primary cardiac lymphoma through cytological examination of pericardial fluid. Confirmatory diagnosis was established through cytology of pericardial effusion, supported by imaging techniques. The patient completed all cycles of chemotherapy and is currently in remission. Conclusions This case highlights the essential role of accurate cytological evaluation by laboratory professionals, which can facilitate early diagnosis and may obviate the need for more invasive procedures such as endomyocardial biopsy.
Open Access
Fungal infection detected from a peripheral blood smear review

October 2, 2025

Mireia Pallarés, Jorge Medina, Marc Garreta, Emma Padilla, Teresa Villalba, Josefa Pérez, Antonio Casabella

Download PDF

Objectives Histoplasmosis is a lung and blood disease caused by a dimorphic fungus, Histoplasma capsulatum , which causes non-specific clinical manifestations making differential diagnosis aimed at its detection difficult. Case presentation We explore the case of a 28-year-old man whose blood test revealed pancytopenia, which led to review of the blood film, which showed yeast-like cytoplasmic inclusions in some of the neutrophils, suggestive of H. capsulatum infection. Given the suspicion, the laboratory expanded tests for the detection of fungal biomarkers such as galactomannan antigen and B-D-glucan, in addition to HIV serology, which were positive. Conclusions This case highlights the importance of the morphological review of the blood film in the laboratory, as it provides very valuable and relevant information for the diagnosis of many diseases. As well as the importance of communication between the different departments in the laboratory.
Open Access
Association between HLA alleles and adverse drug reactions. Mechanisms involved

September 5, 2025

Ana de Malet Pintos-Fonseca, Laura Riesco-Dávila, Serafín Mirete-Bachiller, Israel Nieto-Gañán

Download PDF

Introduction Adverse drug reactions (ADRs) represent a major public health problem. A significant subset of these reactions, particularly delayed-type hypersensitivity reactions and severe cutaneous adverse reactions (SCARs), show a strong association with specific alleles of the human major histocompatibility complex (HLA). The following review aims to summarize the current evidence on the associations between HLA alleles and ADR, covering both well-established associations and those with emerging evidence. The proposed immunological mechanisms for these adverse reactions are also outlined, including hapten/pro-hapten, pharmacological interaction with immune receptors (p-i) and the altered peptide models. Content A systematic literature search was conducted in the PubMed database (MEDLINE) through April 2025, independently by the authors. A consensus was then reached, with a total of 56 articles being used in this review. Summary A division by groups of drugs is established (antiretrovirals, aromatic antiepileptics, allopurinol, antibiotics and other drugs), indicating for each of them the HLA involved, the proposed mechanism, ethnicity in which the association was described and the degree of association. A table is included to facilitate consultation of key information. Outlook HLA alleles play a critical role in the pathogenesis of numerous ADRs, and further studies are needed to clarify HLA-ADRs associations and the mechanisms involved.
Open Access
Urine pH and ammonium paediatric reference intervals in first morning spot urine

September 3, 2025

Lucas Ramón Díaz-Anadón, Julián Rodríguez, Flor Ángel Ordóñez-Álvarez, Helena Gil-Peña, Óscar David Pons-Belda, Leire Cardo

Download PDF

Objectives Urinary acidification plays a crucial role in acid-base homeostasis, its evaluation being necessary in the differential diagnosis of metabolic acidosis. The practical limitations of the functional tests required to confirm an acidification disorder point out the need for a simple screening method for urinary acidification assessment in spot urine. The best candidates are urine pH and ammonium (NH 4 + ), but there are few data on their reference values in spot urine in children. Methods Our study measured urine pH and NH 4 + /creatinine ratio in the first morning fasting urine of 135 healthy children aged between 5 and 14 years. pH was measured by dipstick and potentiometry, concluding that only potentiometric measures were appropriated for assessing urinary acidification in acid-base diseases. Results Median urine pH was 5.67 (interquartile range 5.44–6.01), ranging from 4.90 to 7.60. Median NH 4 + /creatinine ratio was 4,869 μmol/mmol (interquartile range 3,528–5,918). The reference interval for urine pH ranged from 5.01 to 6.88 and the reference interval for NH 4 + /creatinine ratio ranged from 1,646 μmol/mmol to 9,799 μmol/mmol. Conclusions These results supply, for the first time, paediatric reference values for both parameters simultaneously, standardizing the sample and method of choice and providing a clinically useful tool for a preliminary evaluation of urinary acidification.
Open Access
The urine examination: a modern technological test with a very ancient history

September 1, 2025

Massimo Daves, Erika Jani, Rossella Panella, Ruggero Buonocore, Stefano Pastori, Vincenzo Roccaforte

Download PDF

For centuries, the only ‘semeiological and laboratory’ test that the physician had at his disposal to point towards to a diagnosis was the urine test. It was based on the chemical and physical properties evaluation of the sample. During the last decade of the 20th century, the use of flow cytometry opened new perspectives in the diagnostic strategy of urine examination, making it possible to automate a typically manual procedure that was represented by reading the urine sediment under an optical microscope. The combination of fully automated physical chemical and urinary sediment testing has increased the amount of information we can obtain from a simple urine test. Today’s fully automated analyzers have an accurate cell count and an excellent particle differentiation which brought a higher diagnostic reliability. Today’s uranalysis is the product of many scientists, chemists, physicians, that over decades have developed, increased the accuracy, have tried to understand, and give a meaning to all aspects (physical, chemical, and morphological) that can be found in a simple urine test. Our hope is that the urine test will be increasingly re-evaluated for the enormous diagnostic potential it can offer, also in view of a medicine that is increasingly geared to the individual needs of each patient.
Open Access
Farmacogenética y medicina de laboratorio: del gen individual a los estudios genéticos integrales

September 1, 2025

Mercè Brunet Serra, María Isidoro García

Download PDF
Open Access
Beyond mean corpuscular volume: the role of neutrophil and monocyte volume cell population data in the diagnosis of vitamin B12 deficiency in anemic patients

August 22, 2025

Alba Leis-Sestayo, Álvaro Piedra-Aguilera, Laura Jiménez-Añón, Jennifer Rodríguez-Domínguez, Carme García-Martín, Alicia Martínez-Iribarren, Cristian Morales-Indiano

Download PDF
Open Access
The application and challenges of ChatGPT in laboratory medicine

August 15, 2025

Zhili Niu, Xiandong Kuang, Juanjuan Chen, Xin Cai, Pingan Zhang

Download PDF

In recent years, with the rapid development of artificial intelligence technology, chatbots have demonstrated significant potential in the medical field, particularly in medical laboratories. This study systematically analyzes the advantages and challenges of chatbots in this field and delves into their potential applications in disease diagnosis. However, the reliability and scientific nature of chatbots are influenced by various factors, including data quality, model bias, privacy protection, and user feedback requirements. To ensure the accuracy and reliability of output content, it is essential to not only rely on legal frameworks such as the EU AI Act for necessary protection but also to employ two assessment tools, METRICS and CLEAR. These tools are designed to comprehensively evaluate the quality of AI-generated health information, thereby providing a solid theoretical foundation and support for clinical practice.
Open Access
Genomic characterization of Pseudomonas aeruginosa adaptation mechanisms in bronchiectasis patients

August 15, 2025

Alba Muñoz Santa, Xavier Gómez-Arbonés, Ricardo Pifarré Teixidó, Mercè García-González, Alba Bellés Bellés

Download PDF

Objectives Pseudomonas aeruginosa is one of the main causes of chronic bronchial infection (CBI), especially in patients with chronic underlying diseases such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis (BQ). Compared to P. aeruginosa CBI in CF, BQ infection has historically received less attention. The aim of this study was to determine the antibiotic susceptibility profile of 100 isolates recovered from 100 patients with P. aeruginosa CBI BQ and to characterize some of the adaptation mechanisms in 55 isolates by whole genome sequencing (WGS). Methods Susceptibility testing to 10 antipseudomonal agents was done by MicroScan WalkAway broth microdilution system. WGS was performed using the Illumina DNA Prep library preparation kit. Indexed libraries were sequenced on an Illumina MiSeq benchtop sequencer (300 base pairs paired-end reads). Results The most common loss-of-function mutations occurred in genes encoding the MexAB-OprM efflux-pump system, the pvd cluster and the fpvA receptor, and genes involved in twitching motility such as chpA and fimV . Conclusions Our data indicates that P. aeruginosa adapts by accumulating loss-of-function mutations in several genes, resulting in changes to different phenotypes that may guide the development of new alternative treatment therapies.
Open Access
Variante no descrita previamente en el gen COL3A1: causalidad del Síndrome de Ehlers-Danlos tipo Vascular

August 12, 2025

Estrella Gutiérrez Romero, Nuria Padilla Apuntate, Silvia Izquierdo Álvarez

Download PDF

Resumen Objetivos Diagnosticar a través del estudio genético el Síndrome de Ehlers-Danlos de tipo Vascular (SEDV), caracterizado por roturas musculares y arteriales, así como tendencia a la formación de hematomas, piel fina con venas visibles y rasgos faciales acrogénicos y cuya causalidad es debida a variantes patogénicas (VP) en heterocigosis en el gen COL3A1 . Caso clínico Presentamos el caso de un varón que, tras sufrir un ictus, se identifica una variante probablemente patogénica no reportada previamente en el gen COL3A1 , que cambió la sospecha inicial de Síndrome de Marfan por el diagnóstico genético definitivo de SEDV. Conclusiones La variante detectada en el gen COL3A1 podría apoyar la causalidad en el contexto clínico el paciente y proporcionar un mejor manejo terapéutico.
Open Access
Papel del laboratorio clínico en el estudio de nefrolitiasis y cristaluria por mesalazina

August 11, 2025

Ana Isabel Balbuena, Noelia Poveda, Araceli López, María José Ferri

Download PDF

Resumen Objetivos La formación de litiasis urinarias es una complicación relativamente frecuente en los pacientes con enfermedad inflamatoria intestinal (EII). Su origen se debe a varios factores y pueden producir complicaciones de diversa gravedad. Una de las causas es el propio tratamiento farmacológico. Caso clínico Presentamos 6 casos de pacientes con EII tratados con mesalazina que presentaron cólicos renoureterales. En 3 de ellos se produjo la expulsión de litiasis, cuyo análisis mediante EIR (espectroscopia infrarroja), confirmó su composición 100 % mesalazina. En los otros 3 casos se objetivó la presencia de cristaluria en el estudio del sedimento urinario durante el CRU. En 2 de estos pacientes, se analizó el sedimento urinario, previamente desecado, mediante EIR, confirmándose su composición por mesalazina. Conclusiones Aunque se ha descrito la aparición de litiasis con el uso de este fármaco, se desconoce su frecuencia y existen pocos casos publicados. Respecto a la cristaluria por mesalazina, confirmada en dos de los casos presentados, sólo se había documentado un caso anteriormente, debido a la dificultad en su identificación. Queremos incidir en la importancia del estudio del sedimento urinario en el seguimiento de los pacientes en tratamiento con mesalazina, con el fin de identificar la presencia de cristaluria y evitar así complicaciones mayores.
Open Access
Verification of fCAL turbo Buhlmann reagent for determining serum calprotectin

June 30, 2025

Helena Čičak, Željka Šarčević, Ana Sruk, Frane Bukvić, Daria Pašalić, Lora Dukić, Ana-Maria Šimundić

Download PDF

Objectives The aim of this study was to verify Buhlmann fCAL turbo reagent, used for analysing calprotectin in stool, on serum samples. Methods Leftover patients’ serum samples were used. Verification protocol included: precision performed in accordance with Clinical and Laboratory Standards Institute (CLSI) EP15-A3 guidelines; comparison of Buhlmann fCAL turbo and serum GCAL Gentian reagents; verification of reference intervals (RI) proposed from literature (0.68–5.45 mg/L) in accordance with CLSI EP28-A3C guidelines; limit of blank (LoB) and limit of quantitation (LoQ) performed in accordance with CLSI EP17-A2 guidelines; linearity performed in accordance with CLSI EP6-A guidelines; carry-over and lastly, hook effect. Acceptance criteria were based on manufacturer specifications stated in the package insert for the fCAL turbo Buhlmann reagent designed for analysing calprotectin in stool samples. Results The CVs% for precision were within acceptance criteria, ≤10 %. Bland-Altman analysis showed the presence of a bias of 3.4 mg/L (95 % confidence interval 2.00–4.79). The equation for the Passing-Bablok regression was y= −0.01 (−0.08 to 0.06) + 0.37 (0.36–0.40)x, and it showed proportional difference. The obtained LoB was 0 mg/L, while the LoQ was 0.04 mg/L (CV% ≤ 20 %). The method was linear in the range 0.04–4.14 mg/L, and carry-over (0.1 %) and hook effect were not detected. The proposed RI in the literature was verified using 20 leftover patients’ samples. Conclusions Despite being declared for analysing stool samples only, Buhlmann fCAL turbo reagent can be used to determine serum calprotectin. Buhlmann fCAL turbo reagent is not comparable to the GCAL Gentian reagent.
Open Access
Comparison of four different analyzers for prenatal trisomy 21 risk

June 4, 2025

Natalia García-Simón, Cristina Martínez-Payo, Francisco A. Bernabeu-Andreu, Encarnación Donoso-Navarro

Download PDF

Objectives Various analyzers are available for measuring first-trimester combined screening for trisomy 21 (T21) serum biomarkers (free-beta subunit of the human chorionic gonadotropin (β-hCG) and the pregnancy-associated plasma protein A (PAPP-A)). Our aim is to compare the analytical performance of four different analyzers and their false positive rates (FPR) for T21 risk. Methods A 6-month study analyzed data from 1,136 pregnant women for first-trimester combined screening. Serum samples were processed using four analyzers (IMMULITE 2000, Centaur XP, Cobas e-411, KRYPTOR compact PLUS), each with its own risk calculation software. Comparative analyses of the biochemical markers and their multiples of the median (MoMs) were conducted using Passing-Bablok and Bland-Altman methods. Results Significant variability was observed among the analyzers. For free β-hCG, only Centaur XP and KRYPTOR compact PLUS were interchangeable. For PAPP-A, only IMMULITE 2000 and Cobas e-411 were comparable. However, no analyzer pair was interchangeable for both markers simultaneously. Free β-hCG multiples of the median (MoMs) were highest in IMMULITE 2000 (1.85 MoM (IQR: 1.4–2.97)) and lowest in KRYPTOR compact PLUS (1.5 MoM (IQR: 1.23–2.21)). PAPP-A MoMs were lowest in IMMULITE 2000 (0.52 MoM (IQR: 0.38–0.82)) and highest in Cobas e-411 (0.58 MoM (IQR: 0.39–0.90)). In risk assessment, all analyzers detected true T21 cases but varied in their FPR, with Centaur XP (3.8 %), Cobas e-411 (2.5 %) and KRYPTOR compact PLUS (2.3 %) showing a FPR below 5 %. Conclusions Measurement of serum biomarkers by the four analyzers is not interchangeable. KRYPTOR compact PLUS showed the lowest FPR for risk assessment.
Open Access
Utility of PSA in extracellular vesicles as a follow-up biomarker in prostate cancer

January 1, 2000

Amaia Sandúa, José L. Pérez-Gracia, Estibaliz Alegre, Álvaro González

Download PDF

Objectives Prostate-specific antigen (PSA) circulates bound to extracelular vesicles (EVs). Levels of this PSA form (ev-PSA) are higher in prostate cancer (PCa) compared to benign pathologies and healthy controls, being the PSA extracellular vesicles/serum (ev/srm) ratio potentially useful as PCa diagnostic biomarker. We evaluated the utility of ev-PSA as a follow-up biomarker for detecting relapse or monitoring response to systemic treatments in advanced PCa. Methods Samples were obtained sequentially (baseline, response and progression) from 10 patients with advanced PCa undergoing hormonal therapy or chemotherapy. EVs were isolated from serum by Size Exclusion Chromatography. Total PSA (T-PSA) and free PSA (F-PSA) were quantified in serum and EVs in a c602 module of a Cobas 8000 (Roche Diagnostics) using Elecsys immunoassays, and PSA ev/srm ratio was calculated. Results T-PSA in EVs (ev-T-PSA) was quantified in all samples and T-PSA ev/srm ratio median was 1.4 % (Q1-Q3: 1.1–1.9 %). At clinical response, there was not a significant decrease in ev-T-PSA (p=0.055) and neither an increase in T-PSA ev/srm ratio values (p=0.078). During progression, the T-PSA ev/srm ratio decreased significantly with respect to baseline (p=0.037) and clinical response values (p=0.008), although srm-T-PSA and ev-T-PSA concentrations did not change (p=0.625 and p=0.482, respectively). The greatest decrease in srm-T-PSA and ev-T-PSA concentrations was observed in patients undergoing hormonal therapy. Conclusions T-PSA ev/srm ratio could be useful for detecting tumor progression and relapses in advanced PCa. However, its utility as a follow-up biomarker for assessing clinical response to hormonal treatments and chemotherapy would be limited.
Open Access
Design and cost-effectiveness assessment of a model based on point-of-care testing for the improvement of the resolution of hospital emergencies

January 1, 2000

Marta Jimenez-Barragan, Antonio Leon-Justel, Catalina Sanchez-Mora

Download PDF

Objectives Emergency Department (ED) crowding is a quality of care and financial problem. Among its causes are long length of stay in the ED (ED LoS). One of identified causes is prolonged Turnaround Time (TAT) for complementary tests, including laboratory tests. The main aim of this study is to design and validate a cost-effective model for improving resolution of hospital emergencies at the Virgen Macarena University Hospital (VMUH) based on application of point-of-care testing (POCT) on patients classified as priority 3 (P3), according to VMUH’s triage system. Methods P3 patients who met inclusion criteria were randomly assigned into: POCT group (laboratory tests in ED using POCT) or LAB group (laboratory tests in central laboratory). Previously, a correlation study of analytical parameters was done between both groups. Gender, age, reason for consultation, pre-intervention TAT, disposition-decision time (DDT) and ED LoS with or without imaging tests were analysed. A cost study and an extrapolation of strategy at national level were performed. Results The correlation study proved favourable. POCT achieved a median reduction of DDT and ED LoS of 107.00 and 118.50 min respectively. This trend was maintained for non-pain related consultations and irrespective of imaging tests. Use of POCT resulted in a saving of €119.85/episode and a favourable Incremental Cost-Effectiveness Ratio (ICER) of €60.68 saved/ED LoS hour. Applying POCT to 50 % of national P3 EDs, potential savings of €284,206,701.19 were estimated. Conclusions In conclusion, our strategy was shown to reduce DDT and, consequently, ED LoS in a cost-effective way.

Issue 0

Issue 3

Special Issue: Liquid Biopsy: A Step Forward in Laboratory Medicine; Issue Editors: Angel Díaz-Lagares and Wladimiro Jiménez

Special Issue on Bone Biomarkers / Edición Especial sobre Marcadores Óseos

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio publishes special and thematic issues focussed on important and emerging topics in the field of study. The journal has established a rigorous process to ensure that any special issue manuscripts follow the same high-quality standards and peer review processes as regular manuscripts. For further information on the journal’s peer review policy please see the "Instructions for Authors".

Recent Special Issues

Journal Impact Factor	0.9	2024, Journal Citation Reports (Clarivate, 2025)
5-year Journal Impact Factor	1.3	2024, Journal Citation Reports (Clarivate, 2025)
Journal Citation Indicator	0.30	2024, Journal Citation Reports (Clarivate, 2025)
CiteScore	1.4	2024, Scopus (Elsevier B.V., 2025)
SCImago Journal Rank	0.254	2024, SJR (Scimago Lab, 2025; Data Source: Scopus)
Source Normalized Impact per Paper	0.366	2024, CWTS Journal Indicators (CWTS B.V., 2025; Data Source: Scopus)

More information about journal rankings

You can easily submit your manuscript online. Simply go to http://mc.manuscriptcentral.com/almed and you will be guided through the entire submission and publishing process.

Prepare your manuscript according to the Information for Authors and Submission Checklist.

Advances in Laboratory Medicine follows Tier 3 of our Data Sharing Policy. Authors are required to provide a data availability statement. Please refer to the Data Sharing Policy for guidance on how to write a data availability statement.

As a condition of submission, the Template for Ethical and Legal Declarations must be customized by the submitting author on behalf of all others and uploaded as a separate Word file.

If you have any general questions please visit our FAQ page for authors.

For more detailed information please contact editorial.office@semedlab.es

Editor-in-Chief
Wladimiro Jiménez Povedano, Universitat de Barcelona, Barcelona, Spain
wjimenez@clinic.cat

Advisory Co-Editor
Álvaro González Hernández, Clínica Universidad de Navarra, Pamplona, Spain
agonzaleh@unav.es

Associate Editors
Ignacio Arribas Gómez, Hospital Universitario Ramón y Cajal, Madrid, Spain
arribasignacio@gmail.com

Francisco Blanco Vaca, Servei de Bioquímica, Hospital Santa Creu i Sant Pau, Barcelona, Spain
fblancova@santpau.cat

Ángel Díaz Lagares, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) CIBERONC, Santiago de Compostela, Spain
Angel.Diaz.Lagares@sergas.es

Pilar Fernández Calle, Hospital La Paz, Madrid, Spain
pfernandez.hulp@gmail.com

Anna Merino González, Hospital Clínic, Barcelona, Spain
amerino@clinic.es

Advisory Board
Mª Belén Aparicio Hernández, Hospital Universitario de Salamanca, Salamanca, Spain
salaautoinmunidad@yahoo.es

Hugo Azevedo Rocha, Instituto Nacional de Saude Ricardo Jorge, Porto, Portugal
hugodanielrocha@netcabo.pt

Antonio Buño Soto, Hospital La Paz, Madrid, Spain
antoniobuno@gmail.com

María José Calasanz Abinzano, Universidad de Navarra, Pamblona, Spain
mjcal@unav.es

Francesca Canalias Reverter, Universitat Autònoma de Barcelona, Barcelona, Spain
francesca.canalias@uab.cat

Edgardo Carosella, Hemato-Immunology Research Department, CEA, Hospital Saint Louis, Paris, France
edgardo.carosella@cea.fr

Patrocinio Chueca Rodríguez, SEQC-ML, Comite de Comunicacion, Navarra, Spain
patrochueca@gmail.com

Abdurrahman Coskun, Ali Aydinlar University, Istanbul, Turkey
coskun2002@gmail.com

Ana Belén Crujeiras, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain
anabelencrujeiras@hotmail.com

Amitava Dasgupta, University of Texas McGovern Medical School at Houston and Laboratory Services, Memorial-Hermann Hospital at Texas Medical Center, Houston, TX, USA
Amitava.Dasgupta@uth.tmc.edu

Miguel Fernández de Sanmamed Gutiérrez, Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
msanmamed@unav.es

Maurizio Ferrari, Vita-Salute San Raffaele University, Milan, Italy
ferrari.maurizio@hsr.it

Xavier Filella Pla, Hospital Clínic, Barcelona, Spain
xfilella@clinic.cat

Callum G. Fraser, University of Dundee, Dundee Scotland, UK
callum.fraser@nhs.net

Rubén Gómez Rioja, Hospital La Paz, Madrid, Spain
rgrioja@salud.madrid.org

Montserrat González Estecha, Hospital Clínico San Carlos, Madrid, Spain
MONTSE@CMPX.NET

Damien Gruson, Cliniques universitaires Saint-Luc, Brussels, Belgium
damien.gruson@uclouvain.be

Eva Guillén Campuzano, President of the Scientific Committee of SEQC^ML, Barcelona, Spain
eguillen@catlab.cat

Joao Tiago Guimaraes, University of Porto, Porto, Portugal
jtguimar@med.up.pt

Anatoli Horuzsko, Georgia Cancer Center at Augusta University, Augusta, GA, USA
ahoruzsko@augusta.edu

Mercè Ibarz Escuer, Hospital U. Arnau de Vilanova, Lleida, Spain
mibarz.lleida.ics@gencat.cat

Eric S. Kilpatrick, Sidra Medical and Research Center, Doha, Qatar
kilpatricks@cshs.org

Giuseppe Lippi, University Hospital of Verona, Verona, Italy
giuseppe.lippi@univr.it

Eva Martínez Cáceres, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
emmartinez.germanstrias@gencat.cat

Anna Merino González, Hospital Clínic, Barcelona, Spain
amerino@clinic.ub.es

Manuel Morales Ruiz, Hospital Clínic. Barcelona, Barcelona, Spain
morales@clinic.cat

Miguel Angel Moreno Pelayo, Hospital Universitario Ramón y Cajal, Madrid, Spain
mmorenop@salud.madrid.org

Michael Neumaier, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany
michael.neumaier@medma.uni-heidelberg.de

Josep Oriola Ambrós, Hospital Clínic, Barcelona, Spain
joriola@clinic.ub.es

Alberto Pérez-Mediavilla, Universisad de Navarra, Pamplona, Spain
lamediav@unav.es

Mario Plebani, University Hospital Padova, Padova, Italy
mario.plebani@unipd.it

Belén Prieto García, Hospital Universitario Central de Asturias, Oviedo, Spain
prietobelen7@gmail.com

Jose Puzo Foncillas, Hospital General San Jorge, Huesca, Spain
JPUZO@UNIZAR.ES

Rodolfo Alberto Rey, University of Buenos Aires, Buenos Aires, Argentina
rodolforey@cedie.org.ar

Carmen Ricós Águila, Quality Commission, SEQC^ML, Barcelona, Spain
cricosaguila@gmail.com

Francisco Rodriguez Frias, Hospital Vall d'Hebron, Barcelona, Spain
frarodriguez@vhebron.net

Sverre Sandberg, Haukeland University Hospital, Bergen, Norway
sverre.sandberg@noklus.no

Ana-Maria Šimundić, Clinical Hospital Sveti Duh Zagreb, Zagreb, Croatia
am.simundic@gmail.com

Christos Tsatsanis, University of Crete Medical School, Heraklion, Greece
tsatsani@uoc.gr

Rafael Venta Obaya, Hospital San Agustín, Asturias, Spain
rafael.venta@sespa.es

Franz Villarroel Espindola, Fundación Arturo López Pérez, Providencia, Chile
franz.villarroel@falp.org

Ian Young, Queen’s University Belfast, Belfast, UK
i.young@qub.ac.uk

Inès Zidi, University of Tunis El Manar, Tunis, Tunisia
ines.zidi@istmt.utm.tn

Managing Editor
Mariona Panadès, Barcelona, Spain
editorial.office@semedlab.es

Editorial Office
Heike Jahnke, Berlin, Germany
Heike.Jahnke@degruyter.com

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio is covered by the following services:

Baidu Scholar
CABI (over 50 subsections)
Chronos Hub
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO Discovery Service
Google Scholar
J-Gate
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
PubMed
PubMed Central
ReadCube
ScienceON (Korea Institute of Science and Technology Information)
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Summon (ProQuest)
TDNet
WanFang Data
Web of Science - Emerging Sources Citation Index
WorldCat (OCLC)
X-MOL
Yewno Discover

Journal information

Additional information

eISSN:

2628-491X

Languages:

English, Spanish

Publisher:

De Gruyter

Additional information

First published:

February 20, 2020

Publication Frequency:

4 issues per year

eISSN: 2628-491X

Audience(s) for this journal

basic scientists, translational researchers, clinical researchers, industry scientists and professionals in the field of laboratory medicine

Creative Commons

BY 4.0